Results 131 to 140 of about 1,272,186 (267)

Machine learning-based models for tumor mutation burden prediction in gastrointestinal cancers: a systematic review and meta-analysis. [PDF]

Discov Oncol
Rahimi P, Atighi F, Rezaei B, Rezaee H, Abdelbaset M, Nazari F, Zarrehparvar Ghouchani Nezhad S, Moradi Kashkoli M, Ghaffarzadeh A, Taghavi F, Goudarzi P, Samavarchitehrani A, Marashi A, Esmaeili Y, Zhian Zargaran F, Shirdel A, Asadi Anar M, Mousavi S.   +17 more
europepmc   +1 more source

Patient therapy outcome modeling in cancer organoids is improved by cancer‐associated fibroblasts and organoid assembly convolution

Molecular Oncology, EarlyView.
Patient‐derived organoids (PDOs) from pancreatic, colorectal, and gastric cancers were used to evaluate standard and experimental therapies. Incorporating cancer‐associated fibroblasts (CAFs) into organoid cultures improved patient therapy outcome prediction.
Marcin Grochowski, Liudmyla Dolinchuk, Michał Jerzak, Albert Gandurski, Tomasz Grochowski, Weronika Wojtyś, Maciej Zadrożny, Wojciech Kaźmierczak, Małgorzata Lenarcik, Marta Matejak‐Górska, Radosław Samsel, Tomasz Olesiński, Dawid Walerych   +12 more
wiley   +1 more source

Primary carcinoma of the rete testis in a Nellore bull. [PDF]

Vet Res Commun
da Silva NV, Santos RL, de Carvalho TF, de Paula NF, Pereira MF, Micai RA, Pereira GF, Delfiol DJZ, Horr M, Toma HS, Nogueira GM.   +10 more
europepmc   +1 more source

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola, Yasmine Illi, Anna Bircher, Marijn Wilmink, Rachele F. Malagutti, Solenn Ottié, Cordelia Schuler, Pedro A. Ruiz, Cheryl de Vallière, Klaus Seuwen, Gerhard Rogler, Martin Hausmann   +11 more
wiley   +1 more source

THYMIC NEOPLASMS

Journal of Thoracic Surgery, 1956
D B, EFFLER, L J, MCCORMACK
openaire   +2 more sources

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Solid Pseudopapillary Neoplasm of the Pancreatic Head With Atypical Presentation in a Young Woman: A Case Report. [PDF]

Cureus
Abarca Ruiz JW, Borja Velasco CA, Suárez Caicedo MN, Arteaga Morocho EA, Redroban Tufino EJ, Valdivieso Maggi JA, Corella Sanguil PC, Viteri Paredes IP, Barrera Idrovo LA, Salazar Quevedo LG.   +9 more
europepmc   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Outcomes of Mohs Micrographic Surgery Compared to Wide Local Excision for Malignant Melanoma and Melanoma In Situ. [PDF]

Cureus
Goldstein DR, Koch RS, Emam R, Nguyen KT, Raman J, Pirtle FA, Goldstein LD, Tarbox M, Verma KK, Posligua A.   +9 more
europepmc   +1 more source

PARP inhibitors induce a senescence phenotype in non‐small cell lung carcinoma cell lines

FEBS Open Bio, EarlyView.
Talazoparib is the most potent inducer of senescence among different PARP1 inhibitors in human NSCLC cells. In the absence of PARP, no senescence phenotype was observed, demonstrating that PARP1 is necessary for the induction of senescence by this inhibitor.
Camille Huart, Manon Van den Abbeel, Christoph Schifflers, Karim Bouhjar, Andrea Scarmelotto, Alexis Khelfi, Anne‐Catherine Wera, Carine Michiels   +7 more
wiley   +1 more source